Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc (OP:CMNDF)

N/A UNCHANGED
Last Price Updated: 10:24 AM EST, Nov 11, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc

This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split
Psychedelics biotech firm Clearmind Medicine Inc. 
Via Benzinga
Clearmind Medicine Announces Pricing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Featured in "Psychedelics Tonight," Streaming on ALTRD.TV
From Clearmind Medicine Inc.
Via GlobeNewswire
Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements
In connection with recent stock splits, psychedelics biotech Clearmind Medicine Inc. 
Via Benzinga
SciSparc Ltd. Announces Initial Positive Results For The Cocaine Addiction Treatment Of Clearmind Medicine Inc.
SciSparc and Clearmind recently announced the filing of a patent application related to treating cocaine addiction 
Via Benzinga
SciSparc And Clearmind Partnership Yields 3rd Patent Application For The Treating Of Obesity And Metabolic Syndromes
SciSparc Ltd. (NASDAQ: SPRC) announced that Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0), has filed a provisional patent application related to metabolic syndromes including obesity,... 
Via Benzinga
Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration
SciSparc Ltd. (NASDAQ: SPRC) recently announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel... 
Via Benzinga
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment 
Via Benzinga
Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know
Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC Pink: CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd. 
Via Benzinga
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs. 
Via Benzinga
The Bad And The Ugly? The State Of Excessive Alcohol Consumption In The U.S.
Photo by LauritaM on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still... 
Via FinancialNewsMedia
Exposures COVID-19
SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction
SciSparc Ltd. (NASDAQ: SPRC) collaboration with Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) resulted in the filing of a provisional patent application related to treating cocaine... 
Via Benzinga
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction
No dedicated treatment currently available for cocaine addiction 
Via Benzinga
New Psychedelic-Based Alcohol Substitute Approved In India, Produced By Clearmind Medicine
India's Office of the Controller-General of Patents, Designs and Trademarks granted approval for a new compound created by the biotech company Clearmind Medicine Inc. (OTC Pink: CMNDF). 
Via Benzinga
High Hopes For Alcohol Use Disorder Treatment: Clearmind's Successful Pre-IND Meeting With The FDA
The meeting, which took place on May 18 between the psychedelic pharmaceutical biotech company Clearmind Medicine Inc. (CMNDF) and the US Food and Drug Administration marks the completion the pre-IND... 
Via Benzinga
Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company
Medical Psychedelics have made it into Davos, just in time for the World Economic Forum. 
Via Benzinga
Psychedelic Treatment For Alcoholism? Clearmind Medicine And SciSparc Collaboration Yields Positive Results
Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems,... 
Via Benzinga
Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster... 
Via FinancialNewsMedia
Clearmind: Positive Preclinical Evidence For Flagship Psychedelic Molecule, Looks To Human Trials Before Year End
Psychedelics biotech company Clearmind Medicine Inc. 
Via Benzinga
Psyched: Compass, Atai And MindMed Release Q1 Earnings, Phase 3 MDMA Trial Closer To Completion, Enveric Splits Into Two Companies
The psychedelics space got a new glimpse at the financials of some of its heavy hitters with the release of earnings reports for the first quarter of 2022. 
Via Benzinga
Has Clearmind Developed A Psychedelics-Based Drug That Can Treat Alcoholism? The FDA Is Interested
On Wednesday, May 18, Clearmind Medicine Inc. (OTC Pink: CMNDF) will meet with the Center for Drug Evaluation and Research (CDER), a department within the FDA. 
Via Benzinga
SciSparc And Clearmind Reveal Potential To Reduce Alcohol Consumption With Psychedelic Treatment In New Patent Application
Image by Thom Masat on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
SciSparc And Clearmind Medicine Inc. Collaboration Yields New Patent Application For Psychedelic Combination Treatment For Binge Behaviors
Preclinical study results demonstrated the combination of SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption 
Via Benzinga
Alcoholism & Psychedelics: Clearmind Trials Reveal Certain Psychedelics Help Reduce Alcohol Consumption In Mice
Clearmind Medicine Inc. 
Via Benzinga
Clearmind Medicine, SciSparc Launch A Psychedelic Pharma Collaboration
Psychedelic-focused biotech company Clearmind Medicine Inc. (CSE:CMND) (OTC: CMNDF) has signed a collaboration agreement with ... 
Via Benzinga
InvestorNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) to Host Third Event in Psychedelics for Alcoholism Series
Via Investor Brand Network
BioMedNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) Partners with Renowned Expert to Discuss Alcohol Use Disorder and Trauma at Upcoming Virtual Event
Via Investor Brand Network
InvestorNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) Announces Featured Speaker for Psychedelics for Alcoholism series
Via Investor Brand Network
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.